The non-invasive Fore-Sight Elite Absolute Tissue Oximeter is intended for use as an adjunct monitor of absolute regional hemoglobin oxygen saturation of blood under the sensor in individuals at risk for reduced-flow or no-flow ischemic states and is indicated for use as follows:

When used with Large Sensors, the FORE-SIGHT ELITE Oximeter is indicated for use on adults and transitional adolescents ≥40 Kg.
When used with Medium Sensors, the FORE-SIGHT ELITE Oximeter is indicated for use on pediatric subjects ≥ 3 Kg.
When used with Small Sensors, the FORE-SIGHT ELITE Oximeter is indicated for cerebral use on pediatric subjects < 8 Kg and non-cerebral use on pediatric subjects < 5 Kg.

Device Description

The FORE-SIGHT ELITE Absolute Tissue Oximeter measures hemoglobin under the sensor, allowing the clinician to continuously and accurately determine absolute levels of blood oxygenation saturation in the tissue (StO2).

The Fore-Sight Elite Monitor is used together with the preamplifier assembly (cable), and Small, Medium and Large Sensors.

The monitor unit controls the measurement sequence, generating the sensor LED currents and processing the detected light signals after amplification by the dual-channel preamplifier assembly. The Fore-Sight algorithm determines the StO2 values for the tissue under the sensor from the light absorption values and measured patient characteristics. The monitor unit provides simultaneous measurements on up to four Sensors with both numeric and real-time graphical display formats.

The monitor unit is a mains-powered device with a field-replaceable battery pack. A touchscreen user interface allows configuration of the oximeter including audible, on-screen, and dedicated visual alarm indicators. The monitor display can be replicated for simultaneous remote viewing through an auxiliary VGA video output. Measurement data can be exported through various interfaces such as USB and RS-232.

AI/ML Overview

This document is a 510(k) summary for the FORE-SIGHT ELITE Absolute Tissue Oximeter. It states that the device is substantially equivalent to a previously cleared predicate device (K143675). The primary reason for this 510(k) submission is an algorithm update and other minor enhancements.

Based on the provided text, the device measures tissue oxygen saturation (StO2). The studies mentioned are primarily verification activities to demonstrate that the algorithm update did not adversely affect the safety and effectiveness of the device, rather than a clinical study establishing initial accuracy against a gold standard.

Here's the information extracted and organized based on your request:

Acceptance Criteria and Device Performance (as inferred from the document):

Since this is a 510(k) submission for an algorithm update to an already cleared device, the "acceptance criteria" are implied to be that the updated device (specifically, the updated algorithm) performs comparably to or better than the original device, and that its safety and effectiveness are not adversely affected. There aren't explicit numerical acceptance criteria for StO2 accuracy presented in this summary; rather, the focus is on the verification that the changes don't degrade performance.

Criterion	Reported Device Performance
Algorithm Update Impact on Clinical Accuracy	"the algorithm update did not adversely affect the safety and effectiveness of the subject device." (Page 6) "the subject device has the same clinical accuracy when compared to the secondary predicate." (Page 5)
Robustness to Sensor Disruption Scenarios	"the algorithm has been made more robust to better handle sensor disruption scenarios caused by user or environmental factors." (Page 5)
Responsiveness for Pediatric Applications	"It has been made more dynamic for pediatric applications by increasing StO2 responsiveness." (Page 5)
Usability (Human Factors)	"The usability study demonstrated that the intended users can perform primary operating functions and critical tasks of the system without any usability issues that may lead to patient or user harm." (Page 6)
System Requirement Verification (Non-Clinical Performance)	"Completion of all verification and validation activities demonstrated that the subject device meets its predetermined design and performance specifications." (Page 6) "Verification activities performed confirmed that the algorithm upgrade did not adversely affect the safety and effectiveness of the subject device. The measured StO2 parameter was tested using a bench simulation. Additionally, verification of each system requirement was tested after upgrading to the latest algorithm version to verify safety and effectiveness of the subject device. All tests passed." (Page 6-7)
Software Verification	"Software verification was performed per FDA's Guidance for Industry and FDA Staff. 'Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices'. Software was tested at a subsystem level to ensure the safety of the device. All tests passed." (Page 7)

Detailed Study Information:

A table of acceptance criteria and the reported device performance:
- See table above. The document focuses on verification that the changes did not negatively impact the device's performance or safety, rather than presenting accuracy metrics against a ground truth for a new device.
Sample size used for the test set and the data provenance:
- The document mentions "bench simulation" and "verification of each system requirement" but does not specify the sample size for any test sets related to the algorithm performance or the origin of any data used for these tests (e.g., country of origin, retrospective/prospective).
- A "Usability Study" was conducted, but its sample size or data provenance is not specified.
Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- Not applicable as the document does not describe a clinical study against a human-adjudicated ground truth. The tests performed are described as "bench simulation," "system requirement verification," and "software verification."
Adjudication method (e.g., 2+1, 3+1, none) for the test set:
- Not applicable as the document does not describe a clinical study with human readers requiring adjudication.
If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
- No MRMC or human reader comparative effectiveness study is mentioned. This device is an oximeter, not an AI-assisted diagnostic imaging tool with human-in-the-loop analysis.
If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:
- Yes, "The measured StO2 parameter was tested using a bench simulation." (Page 7). Also, "Software was tested at a subsystem level to ensure the safety of the device. All tests passed." (Page 7). The results are qualitative (e.g., "All tests passed," "did not adversely affect").
The type of ground truth used (expert consensus, pathology, outcomes data, etc.):
- For the "bench simulation" of the StO2 parameter, the "ground truth" would likely be derived from the simulated conditions or established reference measurements in the lab, rather than expert consensus, pathology, or outcomes data, which are typically for clinical diagnostic AI. The document does not specify the method for establishing this "ground truth" in the bench simulation.
The sample size for the training set:
- The document does not describe the training of a novel AI model. It discusses an "algorithm update" to an existing device. Therefore, a "training set" in the context of machine learning model development is not mentioned.
How the ground truth for the training set was established:
- Not applicable, as no new training of a machine learning model is described in this submission summary. The "algorithm update" appears to be an enhancement to an existing, cleared algorithm.

Summary

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

February 10, 2021

Edwards Lifesciences, LLC Michelle Ducca Sr. Specialist, Regulatory Affairs One Edwards Way Irvine, California 92614

Re: K203490

Trade/Device Name: FORE-SIGHT ELITE Absolute Tissue Oximeter Regulation Number: 21 CFR 870.2700 Regulation Name: Oximeter Regulatory Class: Class II Product Code: MUD Dated: November 25, 2020 Received: November 27, 2020

Dear Michelle Ducca:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely.

Purva Pandya Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K203490

Device Name FORE-SIGHT ELITE Absolute Tissue Oximeter

Indications for Use (Describe)

When used with Large Sensors, the FORE-SIGHT ELITE Oximeter is indicated for use on adults and transitional adolescents ≥40 Kg.
When used with Medium Sensors, the FORE-SIGHT ELITE Oximeter is indicated for use on pediatric subjects ≥ 3 Kg.
When used with Small Sensors, the FORE-SIGHT ELITE Oximeter is indicated for cerebral use on pediatric subjects < 8 Kg and non-cerebral use on pediatric subjects < 5 Kg.

Type of Use (Select one or both, as applicable)

X Prescription Use (Part 21 CFR 801 Subpart D)

| | Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) Summary – FORE-SIGHT ELITE Absolute Tissue Oximeter

I. Submitter:

Predicate

Devices:

Sponsor:	Edwards Lifesciences LLCOne Edwards WayIrvine, CA 92614
EstablishmentRegistrationNumber:	2015691
Contact Person:	Michelle DuccaSr. Specialist, Regulatory AffairsOne Edwards WayIrvine, CA 92614Telephone: (949) 250-1580Fax: (949) 809-2972
Date Prepared:	November 25, 2020
II.Device Information
Platform Name(Name of theDevice)	Fore-Sight Elite Absolute Tissue Oximeter
Trade Name:	Fore-Sight Elite Absolute Tissue Oximeter
Common Name:	Fore-Sight Elite Monitor
ClassificationName:	Oximeter21 CFR 870.2700
Product Codeand RegulatoryClass:	MUD, Class II
III.Predicate Device
PrimaryPredicate Device:	Fore-Sight Elite Absolute Tissue Oximeter manufactured by CAS MedicaInc. (Now Edwards Lifesciences, K143675, cleared on April 10, 2015).
Additional	HemoSphere Advanced Monitoring Platform (K201446, cleared on

October 1, 2020).

{4}------------------------------------------------

IV. Device Description

The FORE-SIGHT ELITE Absolute Tissue Oximeter measures Device Description: hemoglobin under the sensor, allowing the clinician to continuously and accurately determine absolute levels of blood oxygenation saturation in the tissue (StO2).

The Fore-Sight Elite Monitor is used together with the preamplifier assembly (cable), and Small, Medium and Large Sensors.

V. Indications for Use:

Note: the indication for Use statements are identical for the previously cleared technology (K143675, cleared on April 10, 2015).

FORE-SIGHT ELITE Absolute Tissue Oximeter

-When used with Large Sensors, the FORE-SIGHT ELITE Oximeter is indicated for use on adults and transitional adolescents >40 Kg.
When used with Medium Sensors, the FORE-SIGHT ELITE Oximeter is indicated for use on pediatric subjects ≥ 3 Kg.

{5}------------------------------------------------

When used with Small Sensors, the FORE-SIGHT ELITE Oximeter is indicated for cerebral use on pediatric subjects < 8 Kg and noncerebral use on pediatric subjects < 5 Kg.
Intended Use: The non-invasive Fore-Sight Elite Absolute Tissue Oximeter is intended for use as an adjunct monitor of absolute regional hemoglobin oxygen saturation of blood under the sensor in individuals at risk for reduced-flow or no-flow ischemic states.

The measured parameter for the Fore-Sight Elite Absolute Tissue Oximeter is listed below.

Parameter	Description	Fore-Sight EliteSensor Size	PatientPopulation	HospitalEnvironment
StO2	Tissue Oximetry	Large	Adult only	OperatingRoom,
		Medium	Pediatric	IntensiveCare Unit,
		Small	Pediatric	EmergencyRoom
		Non-AdhesiveSmall	Pediatric

VI. Comparison of Technological Characteristics with the Predicate Devices:

The existing FORE-SIGHT ELITE Absolute Tissue Oximeter (K143675, cleared April 10, 2015), which is the primary predicate for this submission consists of the Fore-Sight Elite Monitor that contains the algorithm and software for tissue oximetry.

The subject and predicate devices are the same with the exception of the following modifications:

I Algorithm update: The algorithm for determining StO2 was updated to the same algorithm that has been recently cleared in the secondary predicate, the HemoSphere Advanced Platform (K201446, cleared on October 1, 2020). There are no new features with the algorithm update, and the subject device has the same clinical accuracy when compared to the secondary predicate.
The difference between the StO2 algorithm of the subject and primary predicate device (K143675 cleared April 10, 2015) is that the algorithm has been made more robust to better handle sensor disruption scenarios caused by user or environmental factors. It has been made more dynamic for pediatric applications by increasing StO2 responsiveness.
Cybersecurity: Cybersecurity updates to the FORE-SIGHT ELITE Absolute Tissue Oximeter include further protection of the

{6}------------------------------------------------

	monitor against brute force attack and enforcement to update thepassword for application-level Biomed account.
	General Monitor Operation Enhancements: Serial Communicationimprovements, improvement of sound playback for medium andlow alarms, and minor bug fixes.
	Graphical User Interface Modifications: The graphical userinterface (GUI) is being updated specifically to include the StO2option in the Reference Alarm Setting Limits pop-up menu.Previously this option was only accessible through a series ofsteps. It is now also available in a one-step action. Additionalchanges to the GUI include the forced password reset pop-up aspart of the cybersecurity update and added system message thatindicates "limits based on StO2" on the Oximeter display.
	Operator's Manual update: is being updated to include and addressthe modifications that are the subject of this 510(k) premarketnotification as well as add Edwards branding and contactinformation.
PerformanceData (Benchand/or Clinical):	The following verification activities were performed in support of asubstantial equivalence determination for the modifications being made aspart of this submission.
	Usability Study
	Usability study was conducted on the FORE-SIGHT ELITE AbsoluteTissue Oximeter per FDA's guidance document "Applying HumanFactors and Usability Engineering to Medical Devices" to investigateprimary operating functions and critical tasks of the updated system forany usability issues that may lead to patient or user harm.
	The usability study demonstrated that the intended users can performprimary operating functions and critical tasks of the system without anyusability issues that may lead to patient or user harm.
	System Verification (Non-Clinical Performance):
	Completion of all verification and validation activities demonstrated thatthe subject device meets its predetermined design and performancespecifications. Verification activities performed confirmed that thealgorithm upgrade did not adversely affect the safety and effectiveness ofthe subject device.

{7}------------------------------------------------

The measured StO2 parameter was tested using a bench simulation. Additionally, verification of each system requirement was tested after upgrading to the latest algorithm version to verify safety and effectiveness of the subject device. All tests passed.

Software Verification

Software verification was performed per FDA's Guidance for Industry and FDA Staff. "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices". Software was tested at a subsystem level to ensure the safety of the device. All tests passed.

Conclusions Overall Conclusion:

The technological characteristics of the predicate and the subject device are identical. The FORE-SIGHT ELITE Absolute Tissue Oximeter has successfully passed performance testing, including the software verification and validation, and bench studies. As such, the FORE-SIGHT ELITE Absolute Tissue Oximeter, including the modifications for the platform is substantially equivalent to the legally marketed predicates.

Regulation Number and Section

§ 870.2700 Oximeter.

(a)
Identification. An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. It may be used alone or in conjunction with a fiberoptic oximeter catheter.(b)
Classification. Class II (performance standards).